Analysts: Gilead Likely to Lead HCV Treatment and 3 More Research Notes to Read

Gilead Sciences (NASDAQ:GILD): After Merck & Co. (NYSE:MRK) reported new results for its PI/NS5A HCV treatment, Wells Fargo does not believe that Merck’s product will prevent Gilead from being a leader in the treatment of the disease in 2014 and beyond; the firm keeps an Outperform rating on Gilead.


Diamondback Energy (NASDAQ:FANG): Brean Capital believes shares of Diamondback Energy will be higher on Tuesday following positive results from it first Middle Sprayberry Shale well and an additional 137 net potential well locations; the firm rates Diamondback Energy shares a Buy, with a $59 price target.


Activision Blizzard (NASDAQ:ATVI): Piper Jaffray says Activision’s Call of Duty Ghosts launched Tuesday morning with initial metacritic scores tracking near 76, a figure which the firm notes is modestly below last year’s version; Piper believes the weak initial reviews may provide a buying opportunity into shares of Activision Blizzard, and the firm keeps an Overweight rating on the stock.


Anadarko Petroleum (NYSE:APC): RBC Capital believes Anadarko’s recent reports of a gassier production mix may weigh on the company’s shares a bit. However, the firm believes that many of the issues facing the company are temporary and should be resolved by early 2014; the firm keeps an Outperform rating on the stock.


Don’t Miss: Here Is How Apple Is Proving Its Commitment to U.S. Manufacturing.